SUMMARY


The management of CINV, as assessed by adherence to antiemetic guidelines, is often suboptimal. Nurses can play a significant role in reducing the incidence of CINV and improving patient care by evaluating patient risk factors for CINV, improving detection and assessment of CINV, encouraging adherence to guidelines, educating patients regarding treatment options, obtaining feedback from patients regarding antiemetic treatment efficacy, and suggesting changes when appropriate. To do this, oncology nurses should remain up to date on changes in guidelines. In this way, reductions in CINV rates can be made through effective prophylactic treatment, improving health care quality and efficiency. 

Acknowledgment The authors wish to thank Jennifer Steeber, PhD, of MedVal Scientific Information Services, LLC, for providing medical writing and editorial assistance. This study and manuscript were supported by funds provided by Eisai Inc. 



Continue Reading


Una Hopkins is administrative director, White Plains Cancer Center in White Plains, New York; and a member of the speakers’ bureau for Eisai Inc (2009-2014) and Bristol-Myers Squibb (2011-2013). Diana Donovan is a nurse practitioner at Dubin Breast Center, Mount Sinai Hospital in New York, New York.
 


REFERENCES


1. Rugo HS. Diagnosing and treating chemotherapy-induced nausea and vomiting: understanding the need and clinical data for best patient cancer care. Oncol Rev. 2014;(suppl):3-8.


2. Tipton JM, McDaniel RW, Barbour L, et al. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2007;11(1):69-78.


3. Hawkins R, Grunberg S. Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes. Clin J Oncol Nurs. 2009;13(1):54-64.


4. Brooks M. Nurses champion guideline-based antiemetic therapy. Medscape Multispecialty Web site. http://www.medscape.com/viewarticle/825047. Accessed September 26, 2014.


5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Antiemesis. Version 2.2014. Fort Washington, PA: National Comprehensive Cancer Network; 2014.


6. Jordan K, Gralla R, Jahn F, Molassiotis A. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol. 2014;722:197-202.


7. Janelsins MC, Tejani MA, Kamen C, et al. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother. 2013;14(6):757-766.


8. Fernández-Ortega P, Caloto MT, Chirveches E, et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life. Support Care Cancer. 2012;20(12):3141-3148.


9. Vidall C, Dielenseger P, Farrell C, et al. Evidence-based management of chemotherapy-induced nausea and vomiting: a position statement from a European cancer nursing forum. Ecancermedicalscience. 2011;5:211.


10. Hassan BA, Yusoff ZB. Negative impact of chemotherapy on breast cancer patients QOL – utility of antiemetic treatment guidelines and the role of race. Asian Pac J Cancer Prev. 2010;11(6):1523-1527.


11. Weaver C, Schiech L, Held-Warmkessel J, et al. Risk for unplanned hospital readmission of patients with cancer: results of a retrospective medical record review. Oncol Nurs Forum. 2006;33(3):E44-E52.


12. Lindley CM, Hirsch JD, O’Neill CV, et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1992;1(5):331-340.


13. Ahern K, Cappo K, Corish N, et al. An analysis of adherence to NCCN clinical practice guidelines in oncology (NCCN guidelines) for antiemesis V.1.2013. Presented at: 39th Annual Congress of the Oncology Nursing Society; May 1-4, 2014; Anaheim, CA.


14. Warr D. Prognostic factors for chemotherapy induced nausea and vomiting. Eur J Pharmacol. 2014;722:192-196.


15. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med. 1993;329(24):1790-1796.


16. Hopkins U. Current clinical practice for chemotherapy-induced nausea and vomiting: understanding the up-to-date evidence-based guidelines for prevention and treatment. Oncol Rev. 2014;(suppl):9-14.


17. Grunberg SM. Chemotherapy-induced nausea and vomiting incidence and prevalence. Am Soc Clin Oncol Educ Book. 2012:541-543.


18. Kav S, Johnson J, Rittenberg C, et al. Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment: an international survey. Support Care Cancer. 2008;16(9):1075-1083.


19. Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15(5):497-503.


20. Kadakia KC, Leal AD, Seisler DK, et al. Antiemetic prescribing practices using a computerized physician order entry system. Support Care Cancer. 2014;22(1):217-223.


21. Rubenstein EB, De Moor C, Cohen L, et al. Outcomes of patients (pts) receiving emetogenic chemotherapy (CT): How do oncologist’s (MD’s) practice patterns of antiemetic prescribing change after pts experience acute or delayed CINV? J Clin Oncol. 2004;22(14S):Abstract 8256.


22. Gilmore JW, Peacock NW, Gu A, et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract. 2014;10(1):68-74.


23. Fujii H, Iihara H, Ishihara M, et al. Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk. Anticancer Res. 2013;33(12):5549-5556.


24. Mertens WC, Higby DJ, Brown D, et al. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol. 2003;21(7):1373-1378.


25. Gralla RJ, Roila F, Tonato M, Herrstedt J. MASCC/ESMO antiemetic guideline 2013. http://mascc.memberclicks.net/assets/documents/mascc_guidelines_english_2013.pdf. Accessed September 26, 2014.


26. Schwartzberg L, Barbour SY, Morrow GR, et al. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 2014;22(2):469-477.


27. Musso M, Scalone R, Crescimanno A, et al. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant. 2010;45(1):123-127.


28. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9(5):188-195.


29. Basch E, Prestrud AA, Hesketh PJ, et al; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189-4198.


30. Grunberg SM. Obstacles to the implementation of antiemetic guidelines. 
J Natl Compr Canc Netw. 2009;7(5):601-605.


31. Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24(27):4472-4478.